NASDAQ:OABI OmniAb (OABI) Stock Price, News & Analysis $6.17 +0.05 (+0.82%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$6.05▼$6.2050-Day Range$4.23▼$6.1752-Week Range$3.07▼$6.20Volume1.01 million shsAverage Volume681,110 shsMarket Capitalization$717.19 millionP/E RatioN/ADividend YieldN/APrice Target$9.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media OmniAb MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside48.6% Upside$9.17 Price TargetShort InterestBearish5.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$405,650 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.52) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector563rd out of 950 stocksBiotechnology Industry9th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.17, OmniAb has a forecasted upside of 48.6% from its current price of $6.17.Amount of Analyst CoverageOmniAb has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.34% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in OmniAb has recently increased by 7.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OABI. Previous Next 3.4 News and Social Media Coverage News SentimentOmniAb has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for OmniAb this week, compared to 1 article on an average week.Search Interest5 people have searched for OABI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows6 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have bought more of their company's stock than they have sold. Specifically, they have bought $405,650.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of OmniAb is held by insiders.Percentage Held by Institutions58.73% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OmniAb are expected to grow in the coming year, from ($0.52) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OmniAb is -20.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OmniAb is -20.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OmniAb Stock (NASDAQ:OABI)OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.Read More OABI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OABI Stock News HeadlinesDecember 24, 2023 | americanbankingnews.comOmniAb (NASDAQ:OABI) Reaches New 1-Year High at $5.98December 15, 2023 | finance.yahoo.comPresident of OmniAb Matthew Foehr Buys 8.2% More SharesDecember 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)December 14, 2023 | finance.yahoo.comOmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics ConferenceDecember 11, 2023 | seekingalpha.comOmniAb: Fabulous Business As A Base For Speculative Biotech InvestorsDecember 8, 2023 | msn.comOmniAb files for $300M mixed shelfDecember 5, 2023 | finance.yahoo.comAre Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 30%?November 20, 2023 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call TranscriptDecember 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)November 15, 2023 | finance.yahoo.comMatthew Foehr Bought 4.1% More Shares In OmniAbNovember 14, 2023 | seekingalpha.comOmniAb, Inc. 2023 Q1 - Results - Earnings Call PresentationNovember 14, 2023 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Analysts Just Slashed Next Year's Revenue Estimates By 14%November 14, 2023 | finance.yahoo.comInsider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 SharesNovember 11, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Technology Stocks: Airgain (AIRG), OmniAb (OABI) and Par Technology (PAR)November 9, 2023 | finance.yahoo.comOmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual EventNovember 9, 2023 | finance.yahoo.comOmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net LossNovember 9, 2023 | finance.yahoo.comOmniAb Reports Third Quarter 2023 Financial Results and Business HighlightsNovember 2, 2023 | finance.yahoo.comOmniAb to Participate in Two Investor Conferences in NovemberNovember 1, 2023 | finance.yahoo.comOmniAb Appoints Steve Love to its Board of DirectorsOctober 31, 2023 | finance.yahoo.comOmniAb Announces Agenda for its Research & Technology Virtual EventOctober 12, 2023 | finance.yahoo.comOmniAb to Hold Research & Technology Virtual Event on November 9September 26, 2023 | msn.comImmunovant drives OmniAb higher after data update; argenx slipsSeptember 25, 2023 | msn.comOmniAb: Hold For GrowthSeptember 17, 2023 | seekingalpha.comOABIW OmniAb, Inc. WT EXP 110127September 5, 2023 | finance.yahoo.comOmniAb to Participate in Two Investor Conferences in SeptemberAugust 18, 2023 | finance.yahoo.comOmniAb President Acquires 2.0% More StockAugust 16, 2023 | finance.yahoo.comNeed To Know: Analysts Just Made A Substantial Cut To Their OmniAb, Inc. (NASDAQ:OABI) EstimatesSee More Headlines Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OABI CUSIPN/A CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployees95Year FoundedN/APrice Target and Rating Average Stock Price Target$9.17 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+48.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,330,000.00 Net Margins-45.99% Pretax Margin-53.64% Return on Equity-8.88% Return on Assets-7.29% Debt Debt-to-Equity RatioN/A Current Ratio4.26 Quick Ratio4.26 Sales & Book Value Annual Sales$59.08 million Price / Sales12.14 Cash FlowN/A Price / Cash FlowN/A Book Value$2.96 per share Price / Book2.08Miscellaneous Outstanding Shares116,240,000Free Float108,101,000Market Cap$717.20 million OptionableNot Optionable Beta-0.40 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Matthew W. Foehr (Age 50)President, CEO & Director Comp: $967.72kMr. Kurt A. Gustafson (Age 55)Executive VP of Finance & CFO Comp: $558.48kMr. Charles S. Berkman J.D. (Age 54)Chief Legal Officer & Secretary Comp: $734.33kMs. Cia McCaffreyVice President of People & TalentDr. Bill Harriman Ph.D.Senior Vice President of Antibody DiscoveryMs. Marie-Cecile van de Lavoir D.V.M.Ph.D., Senior Vice President of Technical Operations & GeneticsDr. Christel Iffland Ph.D.Senior Vice President of Antibody TechnologiesDr. Douglas S. Krafte Ph.D. (Age 65)Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head Ms. Donna Ventura CPASenior Vice President of Corporate ControllerMore ExecutivesKey CompetitorsMaxCyteNASDAQ:MXCTAbsciNASDAQ:ABSIVera TherapeuticsNASDAQ:VERATravere TherapeuticsNASDAQ:TVTXGracell BiotechnologiesNASDAQ:GRCLView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 197,950 shares on 12/18/2023Ownership: 4.728%American Century Companies Inc.Bought 23,626 shares on 11/30/2023Ownership: 0.060%Deutsche Bank AGBought 6,325 shares on 11/24/2023Ownership: 0.500%Graham Capital Management L.P.Bought 35,013 shares on 11/22/2023Ownership: 0.030%Sei Investments Co.Bought 3,034 shares on 11/15/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions OABI Stock Analysis - Frequently Asked Questions Should I buy or sell OmniAb stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OABI shares. View OABI analyst ratings or view top-rated stocks. What is OmniAb's stock price target for 2024? 6 analysts have issued 12 month price objectives for OmniAb's stock. Their OABI share price targets range from $6.00 to $11.00. On average, they predict the company's stock price to reach $9.17 in the next year. This suggests a possible upside of 48.6% from the stock's current price. View analysts price targets for OABI or view top-rated stocks among Wall Street analysts. How have OABI shares performed in 2023? OmniAb's stock was trading at $3.60 on January 1st, 2023. Since then, OABI stock has increased by 71.4% and is now trading at $6.17. View the best growth stocks for 2023 here. When is OmniAb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our OABI earnings forecast. How were OmniAb's earnings last quarter? OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The company had revenue of $5.48 million for the quarter, compared to analysts' expectations of $11.37 million. OmniAb had a negative trailing twelve-month return on equity of 8.88% and a negative net margin of 45.99%. How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OABI) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.